Thyroid cancer is a malignant growth arising in the thyroid gland in the lower front of the neck. Its seriousness depends on the type, extent and the person’s health. A thyroid lump needs assessment, but the diagnosis and treatment cannot be inferred from its appearance. NHS: thyroid cancer definition. Confidence: high for descriptive and safety boundaries; moderate for attributed care pathways; low for a conflict-cleared comparison of products or an individual prognosis.
- Papillary/follicular, medullary and anaplastic cancers require different pathways. NCI: thyroid cancer patient PDQ.
- Ultrasound and tissue sampling answer different questions from thyroid hormone blood tests. NHS: thyroid cancer tests.
- Radioactive iodine and TSH suppression require an individual specialist decision.
- Supplements should not replace or delay cancer assessment or treatment. NCCIH: cancer and complementary approaches.
Table of contents
- Evidence summary
- What thyroid cancer is: nodules and distinct cell types
- Diagnosis and biology: ultrasound, pathology, stage and inherited risk
- Thyroid cancer treatment: surgery, surveillance and subtype-specific therapy
- Supplements and daily support: nutrition is different from cancer treatment
- What is established, and what remains uncertain
- Risks and urgent symptoms: airway, surgery and treatment effects
- Interactions: thyroid hormone, supplements and treatment preparation
- Who needs extra assessment before a treatment decision
- Clinician-led treatment and follow-up: questions to settle before leaving
- Animal and laboratory findings: mechanism is not a patient regimen
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Definition and diagnosis | High descriptive confidence | Institutional education; expert/trial finance gaps | Nodules, pathology and extent have distinct meanings. |
| Treatment pathways | Moderate; attributed clinical context | PDQ reviewer connection; original trials unclosed | Subtype, risk and health guide specialist decisions; no product ranking. |
| Radioiodine/TSH planning | Context with individual limits | Guideline/leaflet contributor and study gaps | Preparation and suppression require a written clinical plan. |
| Supplement efficacy | No independent positive verdict here | Dated public safety context | Safety context does not establish tumor control. |
| Funding | Incomplete contributor/trial chains | Dated institutional and reviewer disclosures | Patient PDQ inherits its professional source’s documented reviewer connection. |
What thyroid cancer is: nodules and distinct cell types
Thyroid nodules are common and usually benign. An ultrasound or biopsy investigates cancer risk, while a thyroid function test checks a different aspect of thyroid health. A nodule label alone is not a cancer diagnosis. Experienced thyroid pathology review can matter when the tissue result is difficult to interpret. NCI: thyroid cancer patient PDQ.
Medullary thyroid carcinoma arises in parafollicular C cells rather than the hormone-producing follicular-cell pathway. Some cases are associated with inherited RET changes and MEN2. Its surveillance can involve calcitonin and CEA; these are not interchangeable with the markers used for other thyroid cancers. NCI: medullary thyroid cancer.
Anaplastic thyroid carcinoma can invade nearby structures quickly. A rapidly enlarging neck mass, altered voice or breathing difficulty needs prompt specialist assessment. Its urgency and treatment planning should not be borrowed from a slower-growing papillary tumor. This umbrella introduces those entities without replacing their distinct specialist evaluations. NCI: anaplastic thyroid cancer.
Diagnosis and biology: ultrasound, pathology, stage and inherited risk
Assessment may include examination, neck ultrasound and fine-needle sampling. Further scans assess extent, while a small camera may examine the vocal cords. Not everyone needs every test. Ask which result confirms the diagnosis, what subtype the pathologist found and whether additional sampling would change the plan. NHS: thyroid cancer tests.
An inconclusive needle result is not a confirmed cancer diagnosis. Genomic tests can sometimes help evaluate an indeterminate nodule; they do not settle every uncertainty. Overdiagnosis of small, slow-growing lesions is a recognized issue. This is a reason for careful risk assessment, not for dismissing a new symptomatic neck change. NCI: thyroid cancer research.
Papillary and follicular cancers are well-differentiated follicular-cell tumors. Their staging includes age as well as tumor, nodes and distant spread. Regional lymph nodes do not automatically imply stage IV. Medullary cancer has a different biology; RET assessment and possible MEN2 evaluation address inherited risk and associated endocrine tumors. NCI: thyroid cancer professional PDQ.
Prior radiation exposure, especially in childhood, and a close family history are relevant to discuss. These risk factors do not diagnose a current lump. Many people cannot identify a single cause. Explain earlier radiation treatments and family diagnoses accurately rather than assuming that a supplement or a past food exposure explains the disease. NHS: thyroid cancer risk context.
Thyroid cancer treatment: surgery, surveillance and subtype-specific therapy
Surgery may remove one lobe or the whole gland; selected neck lymph nodes may also be removed. The extent depends on subtype, spread and health, with the team explaining benefits and burdens. Radiation, medicines and thyroid hormone therapy have different purposes. Ask what problem each proposed treatment is intended to address. NHS: thyroid cancer treatment.
NICE’s 2022 framework permits active surveillance for selected solitary microcarcinomas without nodal disease. This means planned clinical monitoring, not ignoring the diagnosis. Indeterminate sampling may require further investigation or diagnostic surgery. Decisions should fit the actual pathology and imaging; the same pathway does not apply to aggressive or medullary disease. NICE NG230: thyroid recommendations.
Radioactive iodine is a selected treatment for iodine-responsive papillary/follicular disease. Anaplastic disease is not responsive to it. Medullary cancer follows its own surgery and systemic-treatment pathway. Thyroid hormone replacement after gland removal and deliberate TSH suppression are different goals, even when a thyroid hormone medicine is used for both. NCI: thyroid cancer professional PDQ.
Targeted medicines may be considered when the tumor’s biology and clinical circumstances fit. A target does not guarantee benefit, and resistance can develop. Blood pressure, liver function, skin or bowel problems may require monitoring, depending on the drug. This guide does not rank medicines, quantify benefit or provide a complete current approval list. NCI: targeted therapy.
Supplements and daily support: nutrition is different from cancer treatment
Difficulty swallowing, appetite loss or weight changes can make adequate intake difficult. Request assessment before adding restrictions or relying on nutritional drinks. A dietitian can adapt food texture, energy and protein needs to the treatment and symptoms. Nutrition support addresses the person’s condition; it does not establish that a particular product controls cancer. NCI: nutrition and weight changes.
A low-iodine preparation may be requested for radioiodine. It is a treatment-specific instruction, not a permanent cancer diet. Show the nuclear medicine team supplements, seaweed/kelp products and prescribed medicines. Do not stop thyroid hormone or medically prescribed calcium merely because a general leaflet describes a different preparation pathway. CUH: thyroid cancer radioiodine leaflet.
Practical support can include help with meals, transport, appointments and emotional concerns. Record questions about neck comfort, work and recovery so the team can give advice matched to the procedure. A product marketed for “thyroid support” does not replace a documented diagnosis or a prescribed hormone plan.
What is established, and what remains uncertain
A tumor biomarker test and inherited genetic testing answer different questions. Tumor changes may help assess treatment eligibility; germline results can affect relatives and counselling. An uncertain variant or an unavailable tissue sample does not justify guessing a target. Ask whether a finding changes the current plan and whether family testing is indicated. NCI: tumor biomarker testing.
The rationale for TSH suppression weighs recurrence risk against comorbidities and possible bone or cardiac problems. Greater suppression is not automatically better, and it need not remain lifelong for every person. Review the intended target with the treating team rather than adjusting hormone tablets to force a laboratory number. NICE NG230: rationale and impact.
A clinical trial asks a research question; participation does not mean that the intervention is already established as the best option. Ask about the sponsor, eligibility, additional procedures and alternatives. Regulatory authorization, tumor response and longer-term health outcomes are different claims and should not be treated as interchangeable. NCI: clinical trials.
Risks and urgent symptoms: airway, surgery and treatment effects
A new or enlarging neck lump, persistent voice change or worsening throat symptoms needs assessment. Difficulty swallowing or breathing warrants urgent help. These signs can have several causes; do not wait for certainty about cancer before seeking care when breathing is affected. NHS: thyroid cancer symptoms.
After thyroid surgery, major swelling under the wound or difficulty breathing requires emergency assessment. Muscle cramps or numbness/tingling of fingers, toes or mouth can signal a calcium problem and require immediate emergency assessment, following the surgical team’s discharge instructions. Redness, heat or discharge from the wound also needs medical advice. CUH: hemithyroidectomy safety.
Head and neck external-beam radiation can affect swallowing, mouth dryness, taste and surrounding tissues. Some effects develop later, so report persistent changes instead of assuming they are inevitable. The radiation team can discuss supportive measures and rehabilitation; side effects depend on the treated field and treatment plan. NCI: radiation side effects.
During treatments that affect immunity, fever, chills or feeling acutely unwell may need urgent oncology contact. Use the team’s specific instructions. Do not first conceal a possible fever with a nonprescription medicine without discussing it; infection risk cannot be judged from how small the original thyroid tumor was. NCI: treatment-related infection.
Interactions: thyroid hormone, supplements and treatment preparation
Food, caffeine, calcium, iron, antacids and some prescription drugs can affect levothyroxine use. Biotin can interfere with thyroid blood tests. Tell the clinician and laboratory about supplements before testing. Ask a pharmacist for the timing required by your particular prescription; this guide does not provide a dose or withdrawal interval. NHS: levothyroxine.
Herbs and concentrated extracts can interact with anticancer medicines. St John’s wort is one example, but risk depends on the actual drug. Provide a complete list including powders, teas and nonprescription remedies. “Natural” and “thyroid-friendly” labels do not establish compatibility with surgery, radioiodine or systemic treatment. NCI: food and supplement interactions.
Who needs extra assessment before a treatment decision
Radioiodine must not be given during pregnancy. Breastfeeding and future pregnancy/fathering plans require an advance discussion with the nuclear medicine team. Household contacts, carers and travel plans can affect radiation precautions. Obtain individualized written instructions; do not reuse someone else’s separation period or assume ordinary iodine supplements are equivalent to prescribed radioiodine. CUH: thyroid cancer radioiodine leaflet.
People with advanced disease can receive palliative care alongside cancer-directed treatment. This addresses symptoms, practical concerns and emotional support rather than requiring all active care to stop. If swallowing, pain or breathlessness is limiting daily life, ask for help early rather than waiting until the next routine scan. NCI: palliative care.
Clinician-led treatment and follow-up: questions to settle before leaving
Thyroid hormone doses are adjusted using clinical circumstances and blood tests. After total thyroid removal, replacement is an ongoing medical requirement; some people also need it after a lobectomy. Ask who will prescribe, arrange testing and explain results. Do not discontinue a prescription because you feel well or because a supplement claims to restore thyroid function. NHS: levothyroxine.
Follow-up is matched to treatment, remaining thyroid tissue and response. Thyroglobulin can help in selected differentiated-cancer surveillance, but antibodies can interfere with interpretation. A detectable value is not automatically proof of recurrence. Ask how the team combines trends, antibodies and imaging, and which new symptoms require earlier contact. NICE NG230: thyroid recommendations.
Keep a copy of the pathology report and treatment summary. Useful questions include: What exact subtype is this? What is the goal of each treatment? Which medicines must continue? What should trigger urgent contact? Who will review laboratory results? The answers should come from the treating service rather than a general online schedule.
Animal and laboratory findings: mechanism is not a patient regimen
A laboratory effect or an animal experiment can suggest a research direction without showing that an intervention helps a person. Human trials assess safety and outcomes under defined conditions. Phase, eligibility and monitoring matter. A thyroid-cell finding does not establish an oral supplement dose, a cure or compatibility with prescribed oncology treatment. NCI: research phases.
This guide uses clinical education and selected guideline descriptions for context. It excludes sponsored product outcomes from an independent verdict. Study design quality remains a separate question from funding; neither a government host nor an academic affiliation closes the financial chain of every cited trial.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 39 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS: thyroid cancer definition | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 18 May 2023; May 2026 review overdue. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: thyroid cancer symptoms | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 18 May 2023; May 2026 review overdue. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: thyroid cancer tests | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 18 May 2023; May 2026 review overdue. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: thyroid cancer treatment | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 18 May 2023; May 2026 review overdue. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: thyroid cancer risk context | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 18 May 2023; May 2026 review overdue. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: thyroid cancer patient PDQ | NCI routes below. Explicitly derives from professional PDQ. Dated reviewer records include Ipsen funding and Menarini/Stemline supply; no page payment inferred. | United States; NCI, Bethesda, Maryland | Tier 3 — connected reviewer provenance; clinical context only | C provisional. Updated 12 February 2025. PDQ is not a formal guideline; current reviewer contracts and supporting trials remain unclosed. |
| NCI: thyroid cancer professional PDQ | NCI routes below. Leads: Bonetti, Truong, del Rivero. Dated reviewer records include Ipsen funding and Menarini/Stemline supply; no page payment inferred. | United States; NCI, Bethesda, Maryland | Tier 3 — connected reviewer provenance; clinical context only | C provisional. Updated 9 May 2025. PDQ is not a formal guideline; current reviewer contracts and supporting trials remain unclosed. |
| NCI: medullary thyroid cancer | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Posted 27 February 2019. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: anaplastic thyroid cancer | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Posted 27 February 2019. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: thyroid cancer research | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Original body read; publication date not separately closed. Public-service and institutional incentives; no independently cleared product outcome. |
| NICE NG230: thyroid recommendations | See NICE’s accounts and NG230 development disclosure below; individual committee and original-study finance remain unclosed. | England, United Kingdom; NICE, Manchester/London | Tier 2 — clinical context; provisional | C provisional. Published 19 December 2022. Public-service and institutional incentives; no independently cleared product outcome. |
| NICE NG230: rationale and impact | See NICE’s accounts and NG230 development disclosure below; individual committee and original-study finance remain unclosed. | England, United Kingdom; NICE, Manchester/London | Tier 2 — clinical context; provisional | C provisional. Published 19 December 2022. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: thyroid cancer radioiodine leaflet | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | C provisional. Approved 7 March 2023, version 6. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: hemithyroidectomy safety | See CUH’s own accounts below; leaflet allocation, named contributors’ outside interests and trial finance remain unclosed. | United Kingdom; CUH, Hills Road, Cambridge | Tier 2 — clinical context; provisional | C provisional. Approved 26 September 2024, version 2. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: levothyroxine | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | B provisional. Reviewed 6 July 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: tumor biomarker testing | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 14 December 2021. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: targeted therapy | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 31 May 2022. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: radiation side effects | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 15 May 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: nutrition and weight changes | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Actual clinical body read; date not separately closed. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: treatment-related infection | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 23 January 2020. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: palliative care | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Actual clinical body read; date not separately closed. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: food and supplement interactions | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 25 April 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: clinical trials | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 3 November 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: research phases | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 8 November 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI budget | Congressional appropriations through NIH/HHS. The dated page distinguishes enacted funding from requests; it does not allocate money to this disease page. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Institutional budget self-report, updated 14 May 2026; statutory scrutiny and an incentive to explain its public mission. |
| NCI Gift Fund and contributions | NCI accepts public donations through its Gift Fund; stamp-related public support is separate. No current disease-page donor ledger or corporate payment is established here. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own contribution information, updated 27 August 2025; fundraising incentives. Donation authority does not prove a named donor funded a page. |
| NCI website editorial process | The website describes expert and editorial review. Its current public budget and gift routes are listed separately; the process page does not supply contributor contracts. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own editorial-process account, reviewed 24 February 2025; institutional credibility incentives. Financial independence of underlying studies remains unknown. |
| PDQ editorial boards and conflicts | NCI provides nongovernment board members honoraria and travel reimbursement. Conflict declarations and recusal are required, but specific board conflicts are not published. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own process disclosure, updated 1 November 2022. Editorial autonomy is distinct from financial independence; current personal and original-trial chains remain incomplete. |
| NHS national website content policy | The dated national policy identifies DHSC funding and states no advertising or corporate sponsorship; it describes staff/contractor declarations. No individual provider finances are established. | England, United Kingdom; national website jurisdiction | Tier 3 — institutional financial/process self-report | B provisional for the dated self-report. Reviewed 14 October 2022; review due 14 October 2025 has passed. Later restructuring, page allocations and source-study ties are not cleared. |
| NCCIH FY2025 congressional justification | NIH/HHS federal budget route. This historical request is not an enacted current budget; the page explicitly says it no longer reflects current HHS policy. Gifts and page allocation remain unclosed. | United States; NCCIH, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional for historical institutional self-report; budget-advocacy incentives. The proposal cannot establish present appropriations or supplement efficacy. |
| NCCIH: cancer and complementary approaches | See the historical NCCIH fiscal source above; exact education-page allocation, expert interests, and each cited study’s finance are unresolved. | United States; NCCIH, Bethesda, Maryland | Tier 2 — public safety context; provisional | C provisional. Last updated October 2021, distinct from the website footer. Public safety education and institutional incentives; dated synthesis does not independently establish any product outcome. |
| CUH: FY2025–26 audited accounts | NHS commissioning, private/overseas care, research/training, charitable capital and other income; industry/academic partnerships. No leaflet allocation inferred. | United Kingdom; NHS Foundation Trust, Cambridge | Tier 3 — financial self-report/statutory accounts | B provisional. Income notes 2.1–2.3 and partnership text read; care, commercial and budget incentives. |
| NICE: FY2025–26 audited accounts | DHSC/NHS England support plus appraisal/advice fees, research, licences and other income. NG230 allocation unknown. | United Kingdom; NICE, Manchester/London | Tier 3 — financial self-report/statutory accounts | B provisional. Actual income note 6 previously read; budget/service interests. No 2022 committee clearance. |
| NG230: original development funding statement | National Guideline Centre received NICE funding. Individual declarations were required; current contracts and full committee interests remain unclosed. | United Kingdom; NICE/National Guideline Centre | Tier 3 — development financial/process self-report | B for dated funding statement, December 2022. Disclosure procedure is not proof of independent outcomes. |
| Bonetti: dated 2015 author declaration | Andrea Bonetti reports no relationship in this particular manuscript. Article funding and current outside contracts remain unclosed. | Italy; then Mater Salutis Hospital, Legnago; current PDQ names Pederzoli Hospital | Tier 3 — author financial self-disclosure | B provisional for dated self-statement, online 26 October 2015. Coauthors’ ties are not assigned to Bonetti. |
| Truong: dated ARS original disclosure | Minh Tam Truong declares American Board of Radiology travel and NCI PDQ Board honoraria. Complete retained forms and current contracts remain unavailable. | United States; Boston University School of Medicine; ARS original publisher | Tier 3 — author financial self-disclosure | B provisional. 2020 original, pages 1–2. Other panelists’ company ties are not assigned to Truong; society funding unclosed. |
| Del Rivero: Ipsen-funded 2025 trial abstract | Publisher names Ipsen Biopharmaceuticals funding and NCI-affiliated Jaydira del Rivero as coauthor. Her personal payment and institution-specific allocation are unknown. | United States; del Rivero, NCI, Bethesda; ASCO publisher | Tier 4 — manufacturer-funded trial; self-interest | D for sponsored outcomes. Dated 2025 original abstract; publisher-indexed funding/affiliation read, direct 403 and detailed COI link access gap. |
| Bonetti: current own professional biography | Own site reports Pederzoli clinical-trial/accreditation consultancy since 2024 and responsibility for EORTC 2129 TREAT ctDNA. Remuneration, practice/provider ownership and page payments remain unknown. | Italy; own biography identifies Pederzoli and prior Legnago roles | Tier 3 — professional role self-report | B provisional for own dated-role statement; page update date unclosed. Self-presentation/client-recruitment incentives; not a financial receipt. |
| EORTC/Menarini: 2023 TREAT drug-supply statement | Joint announcement says Menarini/Stemline would provide elacestrant for EORTC 2129. Stemline described as wholly owned by Menarini. Delivered supplies, funding totals and personal/page payments unknown. | Belgium: EORTC, Brussels; Italy: Menarini, Florence | Tier 4 — maker-supported trial announcement; self-interest | D for intervention/promotional claims. 19 October 2023 original; drug-supply statement is not a current receipt ledger or outcome. |
| EORTC: own institutional funding | Institutional/corporate/private donors, study/service fees, industry grants and public/European grants. Page financial chart refers to 2023; no Bonetti allocation or current trial receipts established. | Belgium; EORTC AISBL/IVZW, Brussels | Tier 3 — institutional financial self-report | B provisional. Own page timestamp 21 November 2025, chart book-year 2023. Research/fundraising incentives; independence procedure does not clear products. |
| EORTC: own legal/contact identity | Self-issued organizational contact; financial routes stated separately. This address does not establish ownership, a donor ledger or disease-page funding. | Belgium; Avenue Emmanuel Mounier 83/11, 1200 Brussels | Tier 3 — institutional identity self-report | B provisional for actual organizational address; publication update not independently closed. Institutional visibility incentives. |
| Menarini: own corporate identity | Company describes itself as privately owned; ultimate beneficial ownership and trial receipts unclosed. Product-sales/commercialization incentives; no personal payment to the reviewer established. | Italy; A. Menarini Industrie Farmaceutiche Riunite S.r.l., Via Sette Santi 1, Florence | Tier 4 — maker-issued corporate source; self-interest | D for promotional independence; address/identity self-report useful with limits. Current page read; copyright 2025 not a review date. |
Frequently asked questions
Does a neck lump mean thyroid cancer? No. Several conditions cause neck lumps, but a new or enlarging lump needs assessment. Breathing or swallowing difficulty needs urgent help. NHS: thyroid cancer symptoms.
Are all thyroid cancers treated alike? No. Papillary/follicular, medullary and anaplastic disease have different biology and care pathways. NCI: thyroid cancer patient PDQ.
Is medullary thyroid cancer always inherited? No. Some cases involve inherited RET changes; clinical genetics assessment distinguishes that issue from a tumor-only finding. NCI: medullary thyroid cancer.
Does everyone need lifelong TSH suppression? No. Suppression is reviewed against disease risk, response and possible bone/cardiac harms; do not alter tablets yourself. NICE NG230: rationale and impact.
Which symptoms after thyroid surgery are urgent? Major neck swelling, breathing difficulty or cramps/numbness/tingling require immediate emergency assessment, following the surgical team’s discharge instructions. CUH: hemithyroidectomy safety.
Can a supplement replace thyroid cancer treatment? No replacement is established here. Discuss products with the care team and avoid delaying diagnosis or prescribed care. NCCIH: cancer and complementary approaches.
Sources and funding notes
Reviewed 4 October 2026. The source map separates clinical context, institutional finance and dated personal disclosures. PDQ is an editorial synthesis, not a clinical guideline. Indexed primary declarations are explicitly distinguished from fully accessible originals; current contracts and page payments remain unknown. Childhood thyroid cancer, parathyroid cancer and rare subtype-specific treatment plans are outside this umbrella’s full coverage. No personal dose, survival forecast or treatment schedule is provided.
- NHS: thyroid cancer definition — Definition and individualized seriousness.
- NHS: thyroid cancer symptoms — Neck, voice, breathing and swallowing assessment.
- NHS: thyroid cancer tests — Ultrasound, sampling, extent and vocal-cord assessment.
- NHS: thyroid cancer treatment — Surgery and treatment-planning context.
- NHS: thyroid cancer risk context — Radiation/family-history assessment; no prevention estimate.
- NCI: thyroid cancer patient PDQ — Subtype/stage and radioactive-iodine boundaries.
- NCI: thyroid cancer professional PDQ — Histology, RET/MEN2 and subtype-specific care context.
- NCI: medullary thyroid cancer — C-cell origin, RET and subtype-specific markers; dated outcomes excluded.
- NCI: anaplastic thyroid cancer — Rapid local growth and expert assessment; dated survival claims excluded.
- NCI: thyroid cancer research — Indeterminate nodules and overdiagnosis; promotional efficacy claims excluded.
- NICE NG230: thyroid recommendations — Selected diagnostic, surveillance and follow-up context.
- NICE NG230: rationale and impact — Individualized TSH suppression and bone/cardiac limitations.
- CUH: thyroid cancer radioiodine leaflet — Treatment-specific preparation, reproductive and radiation precautions.
- CUH: hemithyroidectomy safety — Bleeding/airway and low-calcium warning symptoms; no generic recovery schedule.
- NHS: levothyroxine — Replacement, drug/food interactions and biotin test interference.
- NCI: tumor biomarker testing — Somatic versus inherited testing and uncertain eligibility.
- NCI: targeted therapy — Drug-dependent adverse effects and resistance; no product comparison.
- NCI: radiation side effects — Head/neck site-specific and late effects.
- NCI: nutrition and weight changes — Swallowing, intake and dietitian support.
- NCI: treatment-related infection — Dated urgent-infection precaution, no personal fever threshold.
- NCI: palliative care — Concurrent symptom and practical care; no survival estimate.
- NCI: food and supplement interactions — Drug-specific interaction precautions; board/study finance unclosed.
- NCI: clinical trials — Research versus established individual benefit.
- NCI: research phases — Human-trial design limits; laboratory signals do not establish a regimen.
- NCI budget — Institutional finance only; not treatment efficacy or author clearance.
- NCI Gift Fund and contributions — Additional institutional funding route and headquarters; no page allocation inferred.
- NCI website editorial process — Editorial process only; not an efficacy study.
- PDQ editorial boards and conflicts — PDQ process and financial limits; PDQ summaries are not formal clinical guidelines.
- NHS national website content policy — National website funding/editorial policy, not hospital accounts or current author contracts.
- NCCIH FY2025 congressional justification — Dated institutional route only; no current expenditure total or private-gift exclusion.
- NCCIH: cancer and complementary approaches — Dated replacement/delay and supplement-interaction safety context; no independent product efficacy verdict.
- CUH: FY2025–26 audited accounts — Institutional revenue only; not contributor or thyroid-trial clearance.
- NICE: FY2025–26 audited accounts — Institutional finance, separate from recommendation and author chains.
- NG230: original development funding statement — Guideline funding and review-process provenance only.
- Bonetti: dated 2015 author declaration — Historical financial declaration only; no platinum treatment claims used.
- Truong: dated ARS original disclosure — Financial provenance only; tonsil-cancer care claims not used.
- Del Rivero: Ipsen-funded 2025 trial abstract — Financial connection only; no lanreotide efficacy or adverse-event result used.
- Bonetti: current own professional biography — Reviewer’s trial role only; protocol inaccessible and no breast-cancer care claims used.
- EORTC/Menarini: 2023 TREAT drug-supply statement — Project-level supply linked to the separately documented reviewer role; efficacy excluded.
- EORTC: own institutional funding — Institutional routes only, separate from project supply and personal remuneration.
- EORTC: own legal/contact identity — Country/legal identity only; contact form not submitted.
- Menarini: own corporate identity — Corporate country and financial-role context only; no product claims used.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.